Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C. Kelaidi C, et al. Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29. Leuk Res. 2018. PMID: 30025278
Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A. Duployez N, et al. Am J Hematol. 2014 Jun;89(6):610-5. doi: 10.1002/ajh.23696. Epub 2014 Mar 8. Am J Hematol. 2014. PMID: 24616160 Free article. Clinical Trial.
Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
Marceau-Renaut A, Guihard S, Castaigne S, Dombret H, Preudhomme C, Cheok M. Marceau-Renaut A, et al. Am J Hematol. 2015 May;90(5):E93-4. doi: 10.1002/ajh.23949. Epub 2015 Feb 17. Am J Hematol. 2015. PMID: 25611491 Free article. Clinical Trial. No abstract available.
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. Debarri H, et al. Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645. Oncotarget. 2015. PMID: 26486081 Free PMC article.
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.
Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A. Ferret Y, et al. Haematologica. 2018 May;103(5):822-829. doi: 10.3324/haematol.2017.183525. Epub 2018 Feb 22. Haematologica. 2018. PMID: 29472349 Free PMC article.
Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.
Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P. Renneville A, et al. Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. Leukemia. 2018. PMID: 29740159 No abstract available.
46 results